Valor pronostico de la biopsia liquida en exosomas circulantes en plasma en el paciente oncológico con diagnostico reciente de metástasis cerebrales

Zusammenfassung

Around 40% of the cancer patients with metastatic tumors will present brain metastases during the course of their disease. Once diagnosed, brain metastases are associated with a decreased overall survival; less than 10% of the patients survive more than 2 years, with a significant impairment in their quality of life.Brain metastases are often associated with immune system impairment. Among other molecules, both STAT3 activity and PD-L1 levels in tumor and immune cells are modulated. The identification of new biomarkers useful in liquid biopsy offers several advantages in brain metastases diagnosis and prognosis, such as their easy accessibility and the possibility of non-invasive dynamic monitoring. Extracellular vesicles have been recently proposed as novel biomarkers especially useful in liquid biopsy due to their secretion in biofluids and their role in cell communication during tumor progression...